← Back to Screener
iRhythm Holdings, Inc. Common Stock (IRTC)
Price$122.61
Favorite Metrics
Price vs S&P 500 (26W)-34.48%
Price vs S&P 500 (4W)0.21%
Market Capitalization$3.96B
All Metrics
P/CF (Annual)49.00x
Book Value / Share (Quarterly)$4.73
P/TBV (Annual)11.13x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.05%
Cash Flow / Share (Quarterly)$1.07
Price vs S&P 500 (YTD)-32.53%
Gross Margin (TTM)70.57%
Net Profit Margin (TTM)-5.96%
EPS (TTM)$-1.41
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-1.41
Revenue Growth (5Y)23.02%
EPS (Annual)$-1.39
ROI (Annual)-5.55%
Gross Margin (Annual)70.57%
Net Profit Margin (5Y Avg)-21.97%
Cash / Share (Quarterly)$18.07
Revenue Growth QoQ (YoY)27.12%
ROA (Last FY)-4.37%
Revenue Growth TTM (YoY)26.24%
EBITD / Share (TTM)$-0.98
ROE (5Y Avg)-59.45%
Operating Margin (TTM)-7.68%
Cash Flow / Share (Annual)$1.07
P/B Ratio25.94x
P/B Ratio (Quarterly)37.43x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.86x
Net Interest Coverage (TTM)-32.60x
ROA (TTM)-4.56%
EPS Incl Extra (Annual)$-1.39
Current Ratio (Annual)4.63x
Quick Ratio (Quarterly)4.34x
3-Month Avg Trading Volume0.60M
52-Week Price Return20.55%
EV / Free Cash Flow (Annual)126.76x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.15
P/S Ratio (Annual)5.30x
Asset Turnover (Annual)0.73x
52-Week High$212.00
Operating Margin (5Y Avg)-22.51%
EPS Excl Extra (Annual)$-1.39
CapEx CAGR (5Y)27.88%
Tangible BV CAGR (5Y)24.88%
26-Week Price Return-30.50%
Quick Ratio (Annual)4.34x
13-Week Price Return-26.38%
Total Debt / Equity (Annual)4.25x
Current Ratio (Quarterly)4.63x
Enterprise Value$4,375.85
Revenue / Share Growth (5Y)19.60%
Asset Turnover (TTM)0.77x
Book Value / Share Growth (5Y)-16.68%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)12.33x
Pretax Margin (Annual)-5.84%
Cash / Share (Annual)$18.07
3-Month Return Std Dev47.29%
Gross Margin (5Y Avg)68.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-29.17%
Net Interest Coverage (Annual)-15.34x
EPS Basic Excl Extra (Annual)$-1.39
P/FCF (TTM)76.45x
Receivables Turnover (TTM)9.60x
EV / Free Cash Flow (TTM)126.76x
Total Debt / Equity (Quarterly)4.25x
EPS Incl Extra (TTM)$-1.41
Receivables Turnover (Annual)9.60x
ROI (TTM)-5.83%
P/S Ratio (TTM)5.30x
Pretax Margin (5Y Avg)-21.86%
Revenue / Share (Annual)$23.35
Tangible BV / Share (Annual)$7.91
Price vs S&P 500 (52W)-9.28%
Year-to-Date Return-29.89%
5-Day Price Return5.29%
EPS Normalized (Annual)$-1.39
ROA (5Y Avg)-18.57%
Net Profit Margin (Annual)-5.96%
Month-to-Date Return5.41%
Cash Flow / Share (TTM)$-2.96
EBITD / Share (Annual)$-0.98
Operating Margin (Annual)-7.68%
LT Debt / Equity (Annual)4.25x
P/CF (TTM)49.00x
ROI (5Y Avg)-29.45%
LT Debt / Equity (Quarterly)4.25x
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)12.15x
P/B Ratio (Annual)37.43x
Inventory Turnover (TTM)12.33x
Pretax Margin (TTM)-5.84%
Book Value / Share (Annual)$4.73
Price vs S&P 500 (13W)-27.07%
Beta1.34x
P/FCF (Annual)114.78x
Revenue / Share (TTM)$23.16
ROE (TTM)-38.33%
52-Week Low$97.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.32
4.33
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
IRTCiRhythm Holdings, Inc. Common Stock | 5.30x | 23.02% | 70.57% | -7.68% | $122.61 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
iRhythm Holdings develops and commercializes the Zio System, an FDA-cleared digital platform for ambulatory cardiac monitoring that combines a wire-free, wearable biosensor with proprietary cloud-based analytics software. The system enables clinicians to diagnose arrhythmias more quickly and efficiently than traditional monitoring methods by continuously recording electrocardiogram data over 14 days. Designed for improved diagnostic accuracy and clinical efficiency, Zio addresses a key need in cardiac care monitoring.